Equillium (EQ) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Equillium (EQ) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 2.0% versus a loss of 75.3%. Equillium is the larger company by market cap ($91.3 million vs $90.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | NMRA |
|---|---|---|
| Share price | $1.44 | $0.4798 |
| Market cap | $91.31M | $90.15M |
| 1-day change | +3.60% | +2.46% |
| YTD return | -7.10% | -73.20% |
| 1-year return | -2.04% | -75.27% |
| 5-year return | -75.63% | — |
| EPS (TTM) | $-0.14 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $3.65 |
| 52-week low | $0.76 | $0.45 |
| Distance from 52-week high | -59.32% | -86.85% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +494.44% | +1179.70% |
| Average volume | 583.72K | 1.19M |
| Shares outstanding | 63.41M | 187.90M |
| Employees | 14 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed NMRA by 73.2 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Healthcare · Biotechnology · 14 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
EQ vs NMRA FAQ
Which is bigger, Equillium or Neumora Therapeutics?
Equillium (EQ) is larger, with a market capitalization of $91.31M compared with $90.15M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, EQ or NMRA?
EQ returned -2.04% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.